de Oliveira Elaine Cristina Fontes, Ribeiro Daniel Dias, Senra Janaína Campos, Dos Reis Fernando Marcos
Universidade Federal de Minas Gerais Hospital das Clínicas Division of Human Reproduction Belo HorizonteMinas Gerais Brazil Division of Human Reproduction, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Universidade Federal de Minas Gerais Hospital das Clínicas Departament of Hematology Belo HorizonteMinas Gerais Brazil Departament of Hematology, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Rev Bras Ginecol Obstet. 2025 Apr 30;47. doi: 10.61622/rbgo/2025rbgo23. eCollection 2025.
This study aimed to evaluate the prevalence of antiphospholipid syndrome (APS) among women experiencing recurrent pregnancy loss (RPL).
A cross-sectional was conducted, reviewing the medical records of 134 women with a history of two or more miscarriages, treated between January 2014 and May 2024 at a tertiary university center in Belo Horizonte, Brazil. APS screening was performed by assessing anticardiolipin (IgG and IgM), lupus anticoagulant, and anti-β2-glycoprotein-1 (IgG and IgM) antibodies, based on Sapporo criteria. All tests were performed during non-pregnant periods and at least 12 weeks after the last miscarriage.
The study included 134 women with a mean age of 33.8 ± 5.7 years. The number of prior miscarriages ranged from 2 to 11 per couple. Among the patients who presented the lupus anticoagulant, only two (1.49%) tested positive in two samples, as per revised Sapporo criteria. Considering IgG and IgM anticardiolipin antibodies, four patients (2.98%) tested positive in two samples according to old Sapporo criteria, with one patient having a positive IgG test in two samples, two having positive IgM in two samples and a single patient having both positive tests. None of the 56 patients tested positive for anti-β2-glycoprotein-1 antibodies in two samples.
The prevalence of antiphospholipid antibodies, in line with revised Sapporo criteria, is low among Brazilian women with recurrent pregnancy loss, consistent with recent studies in literature. Ensuring the appropriateness of diagnostic criteria is crucial to avoid unnecessary treatment with platelet anticoagulants and heparin in this population.
本研究旨在评估复发性流产（RPL）女性中抗磷脂综合征（APS）的患病率。
进行了一项横断面研究，回顾了2014年1月至2024年5月在巴西贝洛奥里藏特的一所高等大学中心接受治疗的134名有两次或更多次流产史的女性的病历。根据札幌标准，通过评估抗心磷脂抗体（IgG和IgM）、狼疮抗凝物和抗β2糖蛋白1抗体（IgG和IgM）进行APS筛查。所有检测均在非孕期且最后一次流产后至少12周进行。
该研究纳入了134名平均年龄为33.8±5.7岁的女性。每对夫妇之前的流产次数为2至11次。在出现狼疮抗凝物的患者中，根据修订的札幌标准，只有两名患者（1.49%）在两个样本中检测呈阳性。考虑到IgG和IgM抗心磷脂抗体，根据旧的札幌标准，四名患者（2.98%）在两个样本中检测呈阳性，一名患者在两个样本中IgG检测呈阳性，两名患者在两个样本中IgM检测呈阳性，一名患者两项检测均呈阳性。56名患者中没有一人在两个样本中抗β2糖蛋白1抗体检测呈阳性。
根据修订的札幌标准，巴西复发性流产女性中抗磷脂抗体的患病率较低，这与文献中的近期研究一致。确保诊断标准的适当性对于避免在该人群中不必要地使用血小板抗凝剂和肝素治疗至关重要。
